Representative Josh Gottheimer (D-New Jersey) recently sold shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on March 6th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.
Representative Josh Gottheimer also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Spotify Technology NYSE: SPOT on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Flywire NASDAQ: FLYW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Disco OTCMKTS: DSCSY on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Shopify NYSE: SHOP on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk NYSE: TLK on 3/19/2025.
- Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 3/19/2025.
Abbott Laboratories Trading Up 1.0 %
NYSE ABT traded up $1.30 on Friday, hitting $131.00. 10,459,999 shares of the company were exchanged, compared to its average volume of 6,044,769. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The company's 50 day moving average price is $130.62 and its 200-day moving average price is $121.84. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The firm has a market capitalization of $227.20 billion, a P/E ratio of 17.12, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.
Abbott Laboratories Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's payout ratio is 30.85%.
Insider Buying and Selling
In other news, SVP Eric Shroff sold 562 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $77,651.54. Following the sale, the senior vice president now directly owns 31,970 shares in the company, valued at approximately $4,417,294.90. The trade was a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Andrea F. Wainer sold 949 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the sale, the executive vice president now directly owns 74,381 shares in the company, valued at $10,277,222.77. The trade was a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 116,449 shares of company stock worth $15,463,316 in the last ninety days. 0.46% of the stock is owned by insiders.
Institutional Investors Weigh In On Abbott Laboratories
A number of institutional investors have recently modified their holdings of ABT. Norges Bank acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $2,373,461,000. T. Rowe Price Investment Management Inc. lifted its position in Abbott Laboratories by 383.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,358,698 shares of the healthcare product maker's stock worth $945,453,000 after purchasing an additional 6,628,310 shares during the period. Raymond James Financial Inc. bought a new position in Abbott Laboratories in the 4th quarter valued at about $635,056,000. GAMMA Investing LLC boosted its position in shares of Abbott Laboratories by 15,420.4% during the 1st quarter. GAMMA Investing LLC now owns 5,102,648 shares of the healthcare product maker's stock worth $676,866,000 after acquiring an additional 5,069,771 shares in the last quarter. Finally, Capital International Investors boosted its holdings in shares of Abbott Laboratories by 3.4% in the 4th quarter. Capital International Investors now owns 67,972,953 shares of the healthcare product maker's stock valued at $7,688,160,000 after purchasing an additional 2,229,026 shares in the last quarter. Institutional investors own 75.18% of the company's stock.
Analyst Ratings Changes
ABT has been the subject of several analyst reports. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a research note on Thursday. Piper Sandler reissued an "overweight" rating and issued a $145.00 price objective (up from $133.00) on shares of Abbott Laboratories in a research note on Thursday. Evercore ISI upped their target price on shares of Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research note on Thursday, January 2nd. Raymond James increased their target price on Abbott Laboratories from $132.00 to $142.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Barclays lifted their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a report on Thursday. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $142.59.
View Our Latest Stock Report on ABT
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
About Abbott Laboratories
(
Get Free Report)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Further Reading
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
